Expression of Efp, VEGF and bFGF in normal, hyperplastic and malignant endometrial tissue

Oncology Reports

Volumn 23, Issue 3, 2010, Pages 795-799

  Dai, Hongying ^a   Zhao, Shuping ^a   Xu, Lin ^a   Chen, Aiping ^a   Dai, Shuzhen ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Basic fibroblast growth factor; Endometrial cancer; Estrogen responsive ring finger protein; Vascular endothelial growth factor

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; RING FINGER PROTEIN; VASCULOTROPIN;

ARTICLE; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; HYPERPLASIA; MIDDLE AGED; RNA, MESSENGER; TRANSCRIPTION FACTORS; UBIQUITIN-PROTEIN LIGASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77349109017     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000700     Document Type: Article

References (21)

1. Creasman WT, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz AP, Ngan HY, Sideri M and Pecorelli S: Carcinoma of the corpus uteri. J Epidemiol Biostat 6: 47-86, 2001.
2. Orimo A, Inoue S, Ikeda K, Noji S and Muramatsu M: Molecular cloning, structure, and expression of mouse estrogen-responsive finger protein Efp. J Biol Chem 270: 24406-24413, 1995.
3. Inoue S, Urano T, Ogawa S, Saito T, Orimo K, Hosoi T, Ouchi, Y and Muramatsu M: Molecular cloning of rat efp: expression and regulation in primary osteoblasts. Biochem Biophys Res Commun 261: 412-418, 1999.
4. Folkman J: Tumor angiogenesis. Adv Cancer Res 43: 175-203, 1985.
5. Fujimoto J, Ichigo S, Hirose R, Sakaguchi H and Tamaya T: Expressions of vascular endothelial growth factor (VEGF) and its mRNA in uterine endometrial cancers. Cancer Lett 134: 15-22, 1998.
6. Fujimoto J, Hori M, Ichigo S and Tamaya T: Expression of basic fibroblast growth factor and its mRNA in uterine endometrial cancers. Invas Metast 15: 203-210, 1995.
7. Fujimoto J, Ichigo S, Sakaguchi H, Hirose R and Tamaya T: Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine endometrial cancers. Cancer Lett 130: 115-120, 1998.
8. Guidi AJ, Abu-Jawdeh G, Tognazzi K, Dvorak HF and Brown LF: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer 78: 454-460, 1996.
9. Chao JI, Kuo PC and Hsu TS: Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J Biol Chem 279: 20267-20276, 2004.
10. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME and Shaul PW: Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 103: 401-406, 1999.
11. Seki N, Kodama J, Hongo A, Miyagi Y, Yoshinouchi M and Kudo T: Vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression are implicated in the angiogenesis of endometrial cancer. Eur J Cancer 36: 68-73, 2000.
12. Dai H, Zhang P, Zhao S, Zang J and Wang B: Regulation of vascular endothelial growth factor and growth by estrogen and antiestrogens through Efp in Ishikawa endometrial carcinoma cells. Oncol Rep 21: 395-401, 2009.
13. Mahavni V and Sood AK: Hormone replacement therapy and cancer risk. Curr Opin Oncol 13: 384-389, 2001.
14. Jun W, Yuko K, Norihisa S, Isao O and Hiroyuka K: Stimulatory effect of estrogen on the growth of endometrial cancer cells is regulated by cell-cycle regulators. J Steroid Biochem Mol Biol 107: 163-171, 2007.
15. Inoue S, Orimo A , Hosoi T, Kondo S, Toyoshima H, Kondo T, Ikegami A, Ouchi Y, Orimo H and Muramatsu M: Genomic binding-site cloning reveals an estrogen-responsive gene that encodes a RING finger protein. Proc Natl Acad Sci USA 90: 11117-11121, 1993.
16. Suzuki T, Urano T, Tsukui T, Horie-Inoue K, Moriya T, Ishida T, Muramatsu M, Ouchi Y, Sasano H and Inoue S: Estrogen-responsive finger protein as a new potential biomarker for breast cancer. Clin Cancer Res 11: 6148-6154, 2005.
17. Nakayama H, Sano T, Motegi A, Oyama T and Nakajima T: Increasing 14-3-3 sigma expression with declining estrogen receptor alpha and estrogen-responsive finger protein expression defines malignant progression of endometrial carcinoma. Pathol Int 55: 707-715, 2005.
18. Bermont L, Lamielle-Musard F, Chezy E, Weisz A and Adessi GL: 17beta-estradiol inhibits forskolin-induced vascular endothelial growth factor promoter in MCF-7 breast adenocarcinoma cells. J Steroid Biochem Mol Biol 78: 343-349, 2001.
19. Garrido C, Saule S and Gospodarowicz D: Transcriptional regulation of vascular endothelial growth factor gene expression in ovarian bovine granulosa cells. Growth Factors 8: 109-117, 1993.
20. Yoshiji H, Harris SR and Thorgeirsson UP: Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 57: 3924-3928, 1997.
21. Soufla G, Sifakis S and Spandidos DA: FGF2 transcript levels are positively correlated with EGF and IGF-1 in the malignant endometrium. Cancer Lett 259: 146-155, 2008.